[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transplantation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,81,103,138,161,183,214,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100201063","international-pediatric-peritoneal-biobank-100201063",false,"NCT01893710","International (Pediatric) Peritoneal Biobank","Inclusion Criteria\n\n* Age 0 to 90 years\n* CKD 5D, peritoneal dialysis and\n* Patients with normal renal function and elective abdominal surgery due to limited abdominal pathology (such as hernia repair, gallstones….)\n* Patients post PD and post Tx\n* Oral and written consent\n* Ability to consent of the adult patient and of the parents and legal guardian of patients not yet of legal age, respectively\n\nExclusion Criteria:\n\n* Abdominal adhesions, malformation and inflammation beyond PD induced changes\n* Patients with disseminated tumour disease\n* Patients with critical heart failure and other medical conditions, where the additional procedure may confer an increased increase risk\n* Pregnancy\n* Preterm babies (below 37 weeks of gestational age)\n* Serum hemoglobin \\\u003C 10 g\u002Fdl in newborns and \\\u003C 8 g\u002Fdl in children and adults",true,"ALL","1 Day","90 Years",{"count":20,"type":21},500,"ESTIMATED","2 Years","OBSERVATIONAL","Within few years the peritoneal membrane of adult peritoneal dialysis (PD) patients undergoes substantial morphological transformation, including progressive fibrosis, vasculopathy and neoangiogenesis. Ultrafiltration capacity steadily declines and ultimately results in PD failure. In children, peritoneal biopsies demonstrating PD associated alterations have not yet been obtained. They, however, should be particularly informative, since secondary tissue and vascular pathology related to ageing or diabetes is absent.\n\nAn international, prospective peritoneal membrane biopsy study in children on PD will therefore be performed. Biopsies will be obtained at time of PD catheter insertion, on occasion of intercurrent abdominal surgery (e.g. hernia repair, catheter exchange) and at time of renal transplantation. Quantitative histomorphometry and tissue protein expression analyses will be correlated with time integrated PD treatment modalities and functional characteristics as well as inflammatory and cardiovascular comorbidity surrogate parameter. Blood will be obtained during clinical routine sampling. Biopsies will be obtained during clinically indicated operations, without substantially increasing operation time and associated surgical risks. The detailed histomorphometry of the PD membrane will give additional information, potentially impacting on the individual PD regime.\n\n3\u002F2018: The analyses of the pediatric PD biopsy demonstrated early and major transformation of the peritoneal membrane with neutral pH low GDP fluids, and significant vasculopathy already in children with CKD stage 5, further progressing with PD. The underlying mechanisms are partly understood, only. In view of these major findings and the numerous open questions, collection of biosamples will be continued in children and also in adult PD patients. The following questions will be addressed: Molecular counterparts of peritoneal semi-permeability, solute and water transport (beyond AQP1), pathomechanisms and molecular and functional impact of peritoneal transformation with low and high GDP fluids, and the respective pathomechanisms and molecular and functional impact of vascular disease in CKD and with different PD fluids. The impact of renal transplantation following PD will be assessed in a subgroup of patients with tenckhoff catheter removal several weeks after transplantation and a functioning graft.",[26,27,28,29],"Kidney Failure, Chronic","Peritoneal Dialysis Complication","Transplantation","Healthy",[31,32,33,34,35],"peritoneal dialysis","parietal peritoneum","omentum","chronic kidney disease","vasculopathy","RECRUITING","2026-04-29",{"date":39,"type":40},"2026-04-30","ACTUAL",{"date":42,"type":40},"2011-02-01",{"date":44,"type":21},"2028-12-31",{"name":46,"class":47},"Heidelberg University","OTHER",26,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100544312","transplant-wellness-program-100544312","NCT06367244","Transplant Wellness Program","Exercise and Wellness Behaviour Change for Solid Organ Transplant: A Hybrid Effectiveness-Implementation Trial of the Transplant Wellness Program","TWP","Inclusion Criteria:\n\n* 18 years of age or older\n* In evaluation or listed (active or temporarily inactive) on the transplant waiting list (kidney or liver) - status 0, 1, or 2\n* Able to provide written informed consent and understand study information in English\n* Approval to exercise from Canadian Society for Exercise Physiology - Clinical Exercise Physiologist (CSEP-CEP)\n* Have access to an internet connected device\n\nExclusion Criteria:\n\n* Not cleared for participation in the TWP by attending physician\n* Unable to provide informed consent\n* Clinical condition that makes the intervention unsafe or infeasible (e.g., unable to follow instruction due to refractory encephalopathy)\n* Unsafe environment for virtual participation\n* Recent variceal bleeding and cannot tolerate prophylaxis with non-selective beta blockers","18 Years",{"count":59,"type":21},420,"INTERVENTIONAL",[62],"NA","Wellness is defined as the active pursuit of activities, choices and lifestyles that lead to a state of overall health. Prehabilitation, or using rehabilitation in the period before surgery, can improve the pre, during, and post operative experience for the patient. Although exercise as prehabilitation has been well established in organ transplant, the investigators believe a multiphase approach will help to better serve patients and support patient wellness in the long-term. Supporting wellness behaviour change, such as exercise, stress reduction, and sleep, is associated with improved quality of life (QoL), mood, and improvements in well-being. Including behaviour change support in an exercise program can help support transplant patients in long-term positive lifestyle changes. The Transplant Wellness Program (TWP) is an exercise behaviour change program that includes additional wellness components such as nutrition, stress reduction, and sleep programs to support overall health and QoL of transplant patients. Specifically, the TWP will implement physical activity and behaviour change support for patients pre- and post-transplant surgery, addressing functional (frailty, indices of fitness, physical activity levels) and mental (anxiety, stress) outcomes to improve overall QoL. The TWP includes a 12-week exercise program that is delivered either pre-transplant or post-transplant, depending on length of time from study enrollment to transplant surgery. In addition to the exercise intervention, the TWP includes maintenance resources (access to group exercise classes, wellness webinars, group wellness coaching etc.), and wellness behaviour change support. The goal of the TWP is to improve outcomes of participants throughout their transplant journey, as well as reduce health services use. Collected outcomes will include program reach, effectiveness measures such as changes in physical fitness, adoption by healthcare practitioners, implementation of the program, and maintenance. In addition, will also collect health care use measures as the investigators believe the TWP will result in the reduction of several health care use outcomes, such as the number of hospital admissions (including intensive care unit admissions), length of hospital stays and emergency room utilization.",[28],[66,67,68,69,70,71],"Organ transplantation","Exercise","Prehabilitation","Health promotion","Behavior change","Rehabilitation","2026-04-27",{"date":37,"type":40},{"date":75,"type":40},"2023-11-16",{"date":77,"type":21},"2033-11",{"name":79,"class":47},"University of Calgary",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":60,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":80},"100598137","effect-of-breathing-exercise-on-pain-and-quality-of-recovery-in-after-transplantation-patients-a-randomized-controlled-trial-100598137","NCT07067580","Effect of Breathing Exercise on Pain and Quality of Recovery in After Transplantation Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18 and over, 65 and under,\n* Those who have had a transplant for the first time,\n* Patients who volunteer to participate in the study will be included in the study.\n\nExclusion Criteria:\n\n* Hemodynamically unstable,\n* Those who may experience physical strain during breathing exercises and have a disease that may cause increased intra-abdominal pressure (e.g. bleeding hemorrhoids, hernias of all kinds, persistent cough, severe back pain, heart diseases, high blood pressure, urinary incontinence, epilepsy),\n* Those with early complications\n* Those with neurological or psychological problems,\n* Those who were transferred to the intensive care unit after surgery,\n* Emergency and unplanned cases will be excluded from the scope of the research.","65 Years",{"count":89,"type":21},60,[62],"The researchers will fill out the \"Patient Introduction Form\" for the patients who agreed to participate in the study after obtaining permission from the experimental group with the \"Informed Consent Form\" the day before the surgery. The breathing exercises will be taught and monitored by the researchers, and the researcher who will implement them is a nurse in the general surgery department. The experimental group will be trained on breathing exercises by the researcher the day before the surgery. The patients will be provided with 1 set (4 breaths) per hour of breathing exercises after the surgery. The patient's vital signs will be monitored before and after the breathing exercise. Patients will not have difficulty during the breathing exercise, and they will be provided with gradual interventions. Pain status will be monitored at 0, 2, 6, 12 and 24 hours during the 24-hour hospital stay. The recovery quality scale will be applied on the 1st and 3rd day after surgery. In the control group, after obtaining permission with the \"Informed Consent Form\" the day before the surgery, the patients who agreed to participate in the study will fill out the \"Patient Introduction Form\" by the researchers, and their pain status will be monitored at 0, 2, 6, 12 and 24 hours during the 24-hour hospital stay after the surgery. The recovery quality scale will be applied on the 1st and 3rd day after surgery. No intervention will be made to the patients in the control group, and they will be provided with routine nursing care provided in the hospital.",[28,93,94],"Pain Management","Quality of Recovery 40","2025-12-12",{"date":97,"type":40},"2025-12-15",{"date":99,"type":40},"2025-08-01",{"date":39,"type":21},{"name":102,"class":47},"Ankara Yildirim Beyazıt University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":87,"enrollmentInfo":110,"targetDuration":4,"studyType":60,"phases":112,"briefSummary":114,"conditions":115,"keywords":122,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":80},"100591115","phase-1-safety-and-early-efficacy-of-ipsc-derived-motor-neuron-progenitor-cells-xs228-in-subacute-spinal-cord-injury-a-phase-i-trial-100591115","NCT06976229","Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial","A Phase I Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells (XS228 Cell Injection) in Patients With Subacute Spinal Cord Injury","Inclusion Criteria:\n\nAge: 18 to 65 years (inclusive), regardless of gender.\n\nEtiology: Cervical (C4) to lumbar (L2) spinal cord injury (SCI) caused by traumatic injury or surgery-related factors.\n\nSeverity:\n\nClassified as ASIA Impairment Scale (AIS) Grades A, B, or C. MRI-confirmed evidence of spinal cord injury.\n\nDisease Stage:\n\nPrimary SCI occurring 14 to 60 days prior to screening (subacute phase).\n\nContraception:\n\nParticipants of childbearing potential (male and female) must agree to use effective non-hormonal contraceptive methods during the trial and for 6 months after trial completion.\n\nCompliance:\n\nVoluntarily participate in the clinical study. Ability to understand and comply with study procedures. Participant or legal guardian can provide written informed consent.\n\nExclusion Criteria:\n\n* Neurological Inability\n\nPrimary spinal cord injury (SCI) during screening with concomitant severe traumatic brain injury precluding neurological function assessment.\n\nRespiratory\u002FCirculatory Instability\n\nHigh cervical SCI (C1-C3) causing respiratory\u002Fcirculatory compromise requiring endotracheal intubation or tracheostomy.\n\nLife-Threatening Multiorgan Dysfunction\n\nConcurrent severe injuries to other organ systems with life-threatening dysfunction.\n\nUnstable Thoracoabdominal Injuries\n\nInjuries to lungs, liver, kidneys, spleen, etc., deemed unstable by the investigator.\n\nPrior Spinal Pathology\n\nHistory of SCI or coexisting spinal disorders (e.g., ankylosing spondylitis, spinal deformities, primary\u002Fmetastatic spinal tumors, spinal vascular malformations, syringomyelia).\n\nLocal Infection\u002FIncreased ICP\n\nActive infection at the lumbar puncture site or intracranial hypertension during screening.\n\nSevere Infections\n\nSepsis, septic shock, or severe pneumonia (per IDSA\u002FATS 2007 diagnostic criteria).\n\nConfounding Neurological\u002FPsychiatric Conditions\n\nParkinson's disease, severe dementia, myasthenia gravis, stroke, Guillain-Barré syndrome, diabetic neuropathy, or other conditions interfering with study assessments.\n\nCardiac Abnormalities (any of the following):\n\nCongestive heart failure (NYHA Class III\u002FIV). Severe uncontrolled arrhythmias (e.g., sick sinus syndrome, third-degree AV block).\n\nUnstable angina or acute myocardial infarction within 3 months prior. Pulmonary Complications\n\nPulmonary hypertension, pulmonary embolism, or suspected embolism during screening.\n\nUncontrolled Hypertension\u002FHypotension\n\nSystolic BP \\>160 mmHg or diastolic BP \\>100 mmHg; or systolic BP \\\u003C90 mmHg or diastolic BP \\\u003C60 mmHg.\n\nActive Autoimmune Diseases\n\nRequiring immunosuppressants (e.g., uncontrolled hyperthyroidism, systemic lupus erythematosus).\n\nImmunosuppressant Non-Compliance\n\nUnwillingness or inability to use immunosuppressants per protocol.\n\nLaboratory Abnormalities (any of the following):\n\nALT\u002FAST \\>2×ULN or total bilirubin \\>2×ULN. eGFR \\\u003C60 mL\u002Fmin\u002F1.73m² (CKD-EPI 2021 formula). APTT\u002FPT \\>2.5×ULN (without anticoagulants). Platelets \\\u003C100×10⁹\u002FL or hemoglobin \\\u003C90 g\u002FL. Allergy\n\nHistory of severe allergies or hypersensitivity to trial drug\u002Fexcipients (human albumin, lactated Ringer's solution).\n\nInfectious Diseases\n\nHBsAg+ with HBV DNA \\>1000 IU\u002FmL; HCV-Ab+; HIV-Ab+; or TP-Ab+. Lumbar Puncture Refusal\n\nUnwillingness to undergo intrathecal administration procedures. Pregnancy\u002FLactation\n\nFemales who are pregnant or breastfeeding. Malignancy\n\nActive malignancy or anticancer therapy within 5 years prior. Recent Clinical Trial Participation\n\nEnrollment in another drug trial within 3 months prior. Investigator Discretion\n\nAny condition deemed unsuitable for participation by the investigator.",{"count":111,"type":21},12,[113],"PHASE1","This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury",[116,117,118,119,120,121,28],"Spinal Cord Injury","Safety","Clinical Trials","Efficacy","Induced Pluripotent Stem Cells","Human Motor Neuron Progenitor",[123,124,125,126,120,127,28],"spinal cord injury","safety","efficacy","clinical trials","Human motor neuron progenitor","2025-11-19",{"date":130,"type":40},"2025-11-25",{"date":132,"type":40},"2025-07-02",{"date":134,"type":21},"2028-05-30",{"name":136,"class":137},"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","INDUSTRY",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":87,"enrollmentInfo":145,"targetDuration":4,"studyType":60,"phases":146,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":80},"100591018","phase-2-efficacy-of-ipsc-derived-motor-neuron-cells-xs228-in-subacute-spinal-cord-injury-a-phase-ii-randomized-controlled-trial-100591018","NCT06974968","Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial","A Phase II Clinical Study Evaluating the Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells (XS228 Cell Injection) in Patients With Subacute Spinal Cord Injury","Inclusion Criteria:\n\n* Age: 18 to 65 years (inclusive), regardless of gender.\n\nEtiology: Cervical (C4) to lumbar (L2) spinal cord injury (SCI) caused by traumatic injury or surgery-related factors.\n\nSeverity:\n\nClassified as ASIA Impairment Scale (AIS) Grades A, B, or C. MRI-confirmed evidence of spinal cord injury.\n\nDisease Stage:\n\nPrimary SCI occurring 14 to 60 days prior to screening (subacute phase).\n\nContraception:\n\nParticipants of childbearing potential (male and female) must agree to use effective non-hormonal contraceptive methods during the trial and for 6 months after trial completion.\n\nCompliance:\n\nVoluntarily participate in the clinical study. Ability to understand and comply with study procedures. Participant or legal guardian can provide written informed consent.\n\nExclusion Criteria:\n\n* Neurological Inability\n\nPrimary spinal cord injury (SCI) during screening with concomitant severe traumatic brain injury precluding neurological function assessment.\n\nRespiratory\u002FCirculatory Instability\n\nHigh cervical SCI (C1-C3) causing respiratory\u002Fcirculatory compromise requiring endotracheal intubation or tracheostomy.\n\nLife-Threatening Multiorgan Dysfunction\n\nConcurrent severe injuries to other organ systems with life-threatening dysfunction.\n\nUnstable Thoracoabdominal Injuries\n\nInjuries to lungs, liver, kidneys, spleen, etc., deemed unstable by the investigator.\n\nPrior Spinal Pathology\n\nHistory of SCI or coexisting spinal disorders (e.g., ankylosing spondylitis, spinal deformities, primary\u002Fmetastatic spinal tumors, spinal vascular malformations, syringomyelia).\n\nLocal Infection\u002FIncreased ICP\n\nActive infection at the lumbar puncture site or intracranial hypertension during screening.\n\nSevere Infections\n\nSepsis, septic shock, or severe pneumonia (per IDSA\u002FATS 2007 diagnostic criteria).\n\nConfounding Neurological\u002FPsychiatric Conditions\n\nParkinson's disease, severe dementia, myasthenia gravis, stroke, Guillain-Barré syndrome, diabetic neuropathy, or other conditions interfering with study assessments.\n\nCardiac Abnormalities (any of the following):\n\nCongestive heart failure (NYHA Class III\u002FIV). Severe uncontrolled arrhythmias (e.g., sick sinus syndrome, third-degree AV block).\n\nUnstable angina or acute myocardial infarction within 3 months prior. Pulmonary Complications\n\nPulmonary hypertension, pulmonary embolism, or suspected embolism during screening.\n\nUncontrolled Hypertension\u002FHypotension\n\nSystolic BP \\>160 mmHg or diastolic BP \\>100 mmHg; or systolic BP \\\u003C90 mmHg or diastolic BP \\\u003C60 mmHg.\n\nActive Autoimmune Diseases\n\nRequiring immunosuppressants (e.g., uncontrolled hyperthyroidism, systemic lupus erythematosus).\n\nImmunosuppressant Non-Compliance\n\nUnwillingness or inability to use immunosuppressants per protocol.\n\nLaboratory Abnormalities (any of the following):\n\nALT\u002FAST \\>2×ULN or total bilirubin \\>2×ULN. eGFR \\\u003C60 mL\u002Fmin\u002F1.73m² (CKD-EPI 2021 formula). APTT\u002FPT \\>2.5×ULN (without anticoagulants). Platelets \\\u003C100×10⁹\u002FL or hemoglobin \\\u003C90 g\u002FL. Allergy\n\nHistory of severe allergies or hypersensitivity to trial drug\u002Fexcipients (human albumin, lactated Ringer's solution).\n\nInfectious Diseases\n\nHBsAg+ with HBV DNA \\>1000 IU\u002FmL; HCV-Ab+; HIV-Ab+; or TP-Ab+. Lumbar Puncture Refusal\n\nUnwillingness to undergo intrathecal administration procedures. Pregnancy\u002FLactation\n\nFemales who are pregnant or breastfeeding. Malignancy\n\nActive malignancy or anticancer therapy within 5 years prior. Recent Clinical Trial Participation\n\nEnrollment in another drug trial within 3 months prior. Investigator Discretion\n\nAny condition deemed unsuitable for participation by the investigator",{"count":89,"type":21},[147],"PHASE2","Purpose: This clinical trial is studying an investigational cell therapy called XS228-a lab-made stem cell product designed to help repair damaged nerves in the spinal cord. The goal is to see if XS228 is safe and can improve movement, sensation, and function in people with recent spinal cord injuries.\n\nStudy Treatment: XS228 contains specialized nerve-supporting cells derived from human stem cells. These cells are injected into the spinal fluid (intrathecal administration) in a single dose.\n\nWho Can Join? Adults aged 18-65 with a spinal cord injury (thoracic or lumbar level) that occurred 2-12 weeks before enrollment. Participants must have severe but incomplete paralysis (ASIA Impairment Scale Grade A , B or C).\n\nStudy Plan:\n\nPhase II (Main Study): About 60 participants will be randomly assigned to receive either XS228 or a placebo (inactive solution) in a 2:1 ratio.\n\nFollow-up: Patients will be monitored for 1 year, with regular check-ups to assess safety, nerve function, and recovery progress.\n\nWhat Researchers Are Looking For:\n\nPrimary Goal: Measure changes in leg and arm function using the ASIA Motor Score at 6 months.\n\nSecondary Goals:\n\nImprovement in ASIA Impairment Scale (AIS) grade (e.g., from \"complete\" to \"incomplete\" paralysis).\n\nRecovery of sensation and bladder\u002Fbowel control. Safety (monitoring for side effects like infections or immune reactions). Exploratory Tests: MRI scans and biomarker tests in spinal fluid to see if the treatment helps nerve regrowth.\n\nWhy This Study Matters: If successful, XS228 could become the first stem cell therapy to promote meaningful recovery in spinal cord injury patients. Currently, no treatments exist to repair nerve damage-this trial aims to change that.",[116,117,119,150,120,121,28,151],"Clinical Trial","RCT",[116,117,125,153,120,127,28,151],"clinical trial","NOT_YET_RECRUITING",{"date":130,"type":40},{"date":157,"type":21},"2028-05-25",{"date":159,"type":21},"2031-05-26",{"name":136,"class":137},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":60,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":80},"100596570","phase-2-clinical-study-of-venetoclax-combined-with-azacitidine-as-bridging-therapy-prior-to-hematopoietic-stem-cell-transplantation-in-patients-with-higher-risk-myelodysplastic-syndromes-100596570","NCT07047183","Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes","A Single-Arm, Prospective Clinical Study of Venetoclax Combined With Azacitidine Followed by Bridging Transplantation in Patients With High-Risk Myelodysplastic Neoplasms With Increased Blasts 2 (MDS-IB2)","Inclusion Criteria:\n\n1. Newly diagnosed MDS confirmed by morphological and immunophenotypic analysis of bone marrow；\n2. Age ≥18 years, any gender；\n3. Bone marrow blasts ≥10%；\n4. IPSS-R score \\>4.5；\n5. ECOG performance status 0-2；\n6. Scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT)；\n7. Adequate major organ function：\n\n   * Cardiac: LVEF ≥50%\n   * Hepatic: Bilirubin ≤1.5×ULN\n   * AST\u002FALT ≤2.5×ULN\n   * Renal: Creatinine clearance ≥60 mL\u002Fmin；\n8. Written informed consent provided by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Extramedullary disease involvement；\n2. Hypersensitivity to any study drugs；\n3. Clinically significant hepatic\u002Frenal dysfunction exceeding inclusion thresholds；\n4. Severe cardiac disease, including congestive heart failure, myocardial infarction, and cardiac insufficiency;\n5. Concurrent malignant tumors of other organs, which can be enrolled if previously cured;\n6. Active tuberculosis or HIV infection;\n7. Concomitant hematologic disorders;\n8. Pregnancy or lactation;\n9. Inability to comply with protocol requirements;\n10. Concurrently participating in other clinical studies.",{"count":169,"type":21},46,[147],"A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)",[173,28],"Myelodysplastic Neoplasms","2025-08-05",{"date":176,"type":40},"2025-08-08",{"date":178,"type":40},"2025-07-01",{"date":180,"type":21},"2029-06-30",{"name":182,"class":47},"Yehui Tan",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":60,"phases":191,"briefSummary":192,"conditions":193,"keywords":197,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":80},"100382293","qualitative-and-quantitative-evaluation-of-vascular-flows-of-radial-ulnar-and-interdigital-arterial-trees-under-normal-and-pathological-conditions-by-3-tesla-mri-100382293","NCT04257747","Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI","FLOWHAND","Inclusion Criteria:\n\n* Adult (≥ 18 years old)\n* patients who has received appropriate information and provided informed consent\n* patients benefiting from social security insurance\n* patients with no contraindications to magnetic resonance imaging\n* healthy volunteer or patient requiring radial forearm flap reconstruction or having received hand allotransplantation.\n\nExclusion Criteria:\n\n* Person with a contraindication to MRI\n* pregnant or breastfeeding woman\n* minors (\\\u003C 18 years)\n* person under guardianship or deprived of liberty by a judicial or administrative decision\n* person with upper limb arteriopathy with the exception of the hand transplant patients group.",{"count":169,"type":21},[62],"Allotransplants of vascularized composite tissues are subject to chronic vascular rejection, which can lead to graft loss. Currently, no imaging technique allows a reproducible quantitative exploration of the arterial trees of the hand, and therefore a satisfactory monitoring of transplants. Since 2014, flow MRI has been applied to the analysis of small-calibre arteries by the Image Processing Team at the Amiens-Picardie University Hospital. Between 2015 and 2017, several acquisitions were made in 3 patients who received facial allotransplantation, and the team recently developed a flow MRI protocol dedicated to the study of arterial trees in the hand.\n\nThe main objective is to measure vascular flows of radial, ulnar and interdigital arterial trees in normal (healthy volunteers) and pathological situations (patients with radial forearm flap reconstruction and patients with hand allotransplantation) using the specifically developed flow MRI protocol.",[194,195,28,196],"Magnetic Resonance Imaging","Vascular Complications","Radial Artery",[198,199,200,201,202,203,204],"vascularized composite allotransplantation","hand allotransplantation","radial forearm flap","magnetic resonance imaging","flow MRI","radial artery","ulnar artery","2025-06-05",{"date":207,"type":40},"2025-06-10",{"date":209,"type":40},"2021-09-01",{"date":211,"type":21},"2029-03",{"name":213,"class":47},"Centre Hospitalier Universitaire, Amiens",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":60,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":80},"100522994","psychological-impact-of-haploidentical-allogeneic-hematopoietic-stem-cell-transplantation-on-donors-100522994","NCT06089850","Psychological Impact of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation on Donors","HAPLOGREF","Inclusion criteria:\n\n* Identical haplo CSH donors ascending (parents) or descending (children)\n* Major identical haplo HSC donors\n* Haplo-identical HSC donors living in mainland France and cared for in the centers participating in the study\n* Haplo-identical HSC donors benefiting from Social Security System.\n* Haplo-identical HSC donors who have signed the consent form\n* \\- Ability to read and write in French\n\nExclusion Criteria:\n\n\\- Insufficient understanding of the French language",{"count":222,"type":21},50,[62],"Allogeneic hematopoietic stem cell transplantation (allo-HSC) is currently one of the only curative treatments for haematological malignancies with a poor prognosis, the realization of which presupposes the identification and availability of a compatible donor. In recent years, haploidentical transplants have been developed, a reliable alternative for patients who do not have 100% compatible donors.\n\nThe development of haplo-identical transplants leads to an exponential increase in the use of intra-family donation. Intrafamilial donation of hematopoietic stem cells (HSC) has the advantages of lower financial cost and faster availability of the graft, thus avoiding the risk of relapse before the procedure. Nevertheless, intrafamilial donation raises clinical and ethical questions. Indeed, the psychological impact of intra-family donation on the donor cannot be overlooked. Thus, in the context of the development of haplo-identical transplants, measuring the impact of donation on donors (ascendants and descendants) will make it possible to assess the relevance of taking psychosocial aspects into consideration in the choice of donors, to assess the psychological impact of haplo-identical donation and to offer psychological support adapted to donors.",[226,28],"Haplo-identical Transplantation",[228,229,230,231,232,233,234],"HSC transplantation","anxiety","depression","donors","hematology","familly","psychic state","2025-04-01",{"date":237,"type":40},"2025-04-02",{"date":239,"type":40},"2024-01-22",{"date":241,"type":21},"2028-01",{"name":243,"class":47},"Assistance Publique - Hôpitaux de Paris",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":252,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":60,"phases":256,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":277},"100579386","digital-delivery-of-person-centered-transitional-care-100579386","NCT06823622","Digital Delivery of Person-centered Transitional Care","Evaluation of the Digital Delivery of Person-centered Transitional Care to Empower Adolescents With Chronic Childhood-onset Diseases: The Digi-STEPSTONES Study","DigiStep","Participants:\n\nArm A - Literate and Swedish-speaking adolescents with asthma\u002Fallergy or went through a solid organ transplantation aged minimum 15 years. Their parents will be asked to fill out one questionnaire (proxy).\n\nArm B:\n\n\\- Literate and Swedish-speaking adolescents with asthma\u002Fallergy or went through a solid organ transplantation aged minimum 15 years. Their parents will be asked to fill out one questionnaire (proxy).\n\nSample size calculation:\n\nArm A: approximately100 patients will be recruited consecutively. Arm B: the approximate sample for individuals who received the intervention in-person is of","15 Years","20 Years",{"count":255,"type":21},100,[62],"Advances in medical care have extended the life expectancy of individuals with congenital and pediatric-onset diseases, leading to an increased need for effective transition programs as these individuals move from pediatric to adult healthcare. The STEPSTONES project in Sweden is designed to evaluate the effectiveness of a person-centered transition program to support teenagers with chronic conditions during this transition. The project's innovative digital adaptation, Digi-STEPSTONES, seeks to address challenges related to accessibility and continuity of care by delivering the program remotely. This study will assess the non-inferiority of the digital program compared to traditional, in-person care, focusing on outcomes such as patient empowerment, transition readiness, and quality of life. Additionally, the project will explore the implementation and scalability of the digital transition model across various chronic conditions. Preliminary studies have highlighted the importance of structured, person-centered care in improving empowerment and other outcomes in adolescents with chronic illnesses. The Digi-STEPSTONES project aims to provide crucial evidence for the digital delivery of transition programs, potentially enhancing the accessibility and effectiveness of care for young people with chronic conditions in Sweden.",[259,28],"Asthma in Children",[261,262,263,264,265,266,267],"Transition","Transfer","Chronic condition","Adolescents","Youth","Young people","Transition program","2025-02-07",{"date":270,"type":40},"2025-02-12",{"date":272,"type":40},"2024-10-01",{"date":274,"type":21},"2028-09-30",{"name":276,"class":47},"Göteborg University",2]